Cyclosporin for severe childhood atopic dermatitis:: short course versus continuous therapy

被引:196
作者
Harper, JI
Ahmed, I
Barclay, G
Lacour, M
Hoeger, P
Cork, MJ
Finlay, AY
Wilson, NJE
Graham-Brown, RAC
Sowden, JM
Beard, AL
Sumner, MJ
Berth-Jones, J
机构
[1] Great Ormond St Hosp Children, Dept Paediat Dermatol, London WC1N 3JH, England
[2] Walsgrave Gen Hosp, Dept Dermatol, Coventry CV2 2DX, W Midlands, England
[3] Royal Hallamshire Hosp, Dept Mol & Genet Med, Sheffield S10 2JF, S Yorkshire, England
[4] Univ Wales Hosp, Dept Dermatol, Cardiff CF4 4XW, S Glam, Wales
[5] Royal Liverpool Univ Hosp, Dept Dermatol, Liverpool L69 3BX, Merseyside, England
[6] Leicester Royal Infirm, Dept Dermatol, Leicester LE1 5WW, Leics, England
[7] Wrexham Maelor Hosp, Dept Dermatol, Wrexham LL13 7TD, Wales
[8] Novartis Pharmaceut UK Ltd, Surrey GU16 5SG, England
关键词
atopic dermatitis; childhood; cyclosporin; Rule of Nines; SASSAD; short-course therapy;
D O I
10.1046/j.1365-2133.2000.03241.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Cyclosporin (CyA) has been shown to be highly effective and well tolerated in the short-term treatment of severe childhood atopic dermatitis; however, there is limited experience in its longer-term use, The aim of this study was to compare multiple short courses of CyA with continuous therapy for 1 year, with respect to efficacy, safety, tolerability and quality of life, Children aged 2-16 years, with a diagnosis of severe atopic dermatitis refractory to topical steroid therapy, were randomly assigned to receive short course therapy (multiple courses of 12 weeks) or continuous therapy, The starting dose and maximum dose for all patients was 5 mg/kg per day, Disease activity was monitored using the Six Area Six Sign Atopic Dermatitis score and the 'Rule of Nines' area score, Pruritus, sleep disturbance and irritability were measured using visual analogue scales, and topical therapy was monitored, Safety measurements included monitoring of serum creatinine, blood pressure and adverse events, Forty patients were included in the efficacy analysis, 21 of whom were randomized to the short course group (of whom six were withdrawn) and 19 to the continuous group (of whom five were withdrawn), Significant improvements were seen in all efficacy parameters at every time-point, There were no significant differences between groups, although the improvement was more consistent in the continuous arm, In the short course arm, 7 out of 21 patients could be managed by at least two short courses, The remaining 14 patients includes 12 who could not be controlled by at least two short courses, one patient who failed td return after week 12 and another patient who was withdrawn at week 4 due to an adverse event, Quality of life improved for both the children and their families, Tolerability was considered good or very good in at least 80% of the patients at week 12 and at the end of the study, No clinically significant change was seen in mean serum creatinine and no change was seen in mean blood pressure in either group, CyA is effective in controlling severe atopic dermatitis in children over a 1-year period and is well tolerated, More consistent control is achieved with continuous treatment; however, short course therapy was adequate for some patients, indicating that treatment should be tailored to the individual patient's needs, Short course treatment may produce prolonged remission in some cases and reduce the cumulative exposure to the drug.
引用
收藏
页码:52 / 58
页数:7
相关论文
共 10 条
  • [1] Cyclosporine in severe childhood atopic dermatitis: A multicenter study
    BerthJones, J
    Finlay, AY
    Zaki, I
    Tan, B
    Goodyear, H
    LewisJones, S
    Cork, MJ
    Bleehen, SS
    Salek, MS
    Allen, BR
    Friedmann, P
    Harper, J
    Camp, RDR
    Smith, S
    GrahamBrown, RAC
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (06) : 1016 - 1021
  • [2] Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis
    BerthJones, J
    GrahamBrown, BAC
    Marks, B
    Camp, RDR
    English, JSC
    Freeman, K
    Holden, CA
    Rogers, SCF
    Oliwiecki, S
    Friedmann, PS
    LewisJones, MS
    Archer, CB
    Adriaans, B
    Douglas, WS
    Allen, BR
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1997, 136 (01) : 76 - 81
  • [4] FINLAY AY, 1996, J EUR ACAD DERMATOL, V7, P149
  • [5] TRADITIONAL CHINESE MEDICINE FOR ECZEMA
    HARPER, J
    [J]. BRITISH MEDICAL JOURNAL, 1994, 308 (6927) : 489 - 490
  • [6] LEWISJONES MS, 1995, BRIT J DERMATOL, V132, P942
  • [7] WHAT DO MEMBERS OF THE NATIONAL-ECZEMA-SOCIETY REALLY WANT
    LONG, CC
    FUNNELL, CM
    COLLARD, R
    FINLAY, AY
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1993, 18 (06) : 516 - 522
  • [8] Reynolds NJ, 1997, J ROY COLL PHYS LOND, V31, P241
  • [9] CYCLOSPORINE GREATLY IMPROVES THE QUALITY-OF-LIFE OF ADULTS WITH SEVERE ATOPIC-DERMATITIS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    SALEK, MS
    FINLAY, AY
    LUSCOMBE, DK
    ALLEN, BR
    BERTHJONES, J
    CAMP, RDR
    GRAHAMBROWN, RAC
    KHAN, GK
    MARKS, R
    MOTLEY, RJ
    ROSS, JS
    SOWDEN, JM
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1993, 129 (04) : 422 - 430
  • [10] DOUBLE-BLIND, CONTROLLED, CROSSOVER STUDY OF CYCLOSPORINE IN ADULTS WITH SEVERE REFRACTORY ATOPIC-DERMATITIS
    SOWDEN, JM
    BERTHJONES, J
    ROSS, JS
    MOTLEY, RJ
    MARKS, R
    FINLAY, AY
    SALEK, MS
    GRAHAMBROWN, RAC
    ALLEN, BR
    CAMP, RDR
    [J]. LANCET, 1991, 338 (8760) : 137 - 140